Is CSL the best blue-chip share on the S&P/ ASX200?

An Australian share market success story.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the CSL Limited (ASX: CSL) share price being down 17% from its all-time highs, it still remains one of Australia's greatest ASX success stories.

Headquartered in Melbourne, CSL has become a global biotech company by focussing on "saving lives and protecting the health of people who were stricken with a range of serious and chronic medical conditions". This focus has led the company's share price to grow at an annualised rate of 19.3% over the last decade, excluding its growing dividend.

The company has a number of products on the market, however its core product is its blood plasma collection business. Analysts believe that this business can grow by high single digits for the foreseeable future. Because of this robust growth the company is aiming to open between 30 to 35 new collection centres this financial year.

CSL currently has five new products moving into human clinical trials. The company has a strong history of investing in research and development (R&D), in order to generate a diverse and growing revenue base. At 31 December 2018, CSL spent 8.7% of total operating revenue on R&D.

A financial key

One of the keys to CSL's share price success is the exceptional 42% return-on-equity (RoE) that it generates. This is possible because the company has used debt to leverage its assets. Without this debt the RoE would be a more moderate 16%.

By historical measures the cost of borrowing has been extremely low for a number of years now. This has enabled companies like CSL to use debt to fund some of their growth. One benefit that CSL has over other companies is that its products are less cyclical and it has strong cash flows. This enables the company to service its interest payments.

For FY19 CSL is targeting the upper end of its full year profit guidance. This would represent 13% year on year growth to between US$1,880 million and US$1,950 million. Shares currently trade around 32x estimated forward earnings and offer an unfranked dividend yield of 1%.

Foolish bottom line

Although CSL trades on a rich valuation compared to its current earnings growth, the strong track record and long term prospects of the company are sound. I'd like to buy shares cheaper than they are today, however it is important to note that high quality companies like CSL generally trade at a premium.

If you like the sound of CSL, here are some other high quality growth companies.

Lloyd Prout has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man has computer-generated images rushing through his head indicating an AI (Artificial Intelligence) concept of a communication network.
Technology Shares

ASX investors are obsessed with Nvidia shares! Here's why

The global chipmaker reported a 94% increase in annual revenue in the third quarter.

Read more »

A man wearing a red jacket and mountain hiking clothes stands at the top of a mountain peak and looks out over countless mountain ranges.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another disappointing day for ASX investors this Thursday.

Read more »

two racing cars battle to take first place on a formula one track with one tailing the the leader and looking to overtake the car.
Opinions

Down 21% in 2024. This ASX 300 stock looks like a money-making monster

Profits are expected to plunge, but the future could still be bright.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
52-Week Lows

Down 68% from highs, this ASX 200 stock just hit a 4-year low. Time to pounce?

Is this beaten down stock a buy? Let's see what one leading broker is saying.

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Share Gainers

Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today

These shares are having a good session on Thursday. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Accent, Sayona Mining, Web Travel, and Weebit Nano shares are dropping today

These shares are having a tough time on Thursday. Why are they being sold off?

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Share Market News

Insider buying alert: 3 ASX 200 shares directors are snapping up right now

Directors in some of Australia's blue-chip businesses aren't shying away from the market.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Guess which beaten down ASX share is rocketing 11% today

Why are investors buying this beaten down stock? Let's find out.

Read more »